The estimated Net Worth of Douglas K Neuro Line Partne... is at least $27.9 Millón dollars as of 11 December 2020. Douglas Partne owns over 64,624 units of Denali Therapeutics Inc stock worth over $10,382,770 and over the last 6 years Douglas sold DNLI stock worth over $17,475,067.
Douglas has made over 3 trades of the Denali Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Douglas sold 64,624 units of DNLI stock worth $5,178,967 on 11 December 2020.
The largest trade Douglas's ever made was selling 255,000 units of Denali Therapeutics Inc stock on 19 June 2020 worth over $6,303,600. On average, Douglas trades about 113,925 units every 35 days since 2019. As of 11 December 2020 Douglas still owns at least 383,411 units of Denali Therapeutics Inc stock.
You can see the complete history of Douglas Partne stock trades at the bottom of the page.
Over the last 7 years, insiders at Denali Therapeutics Inc have traded over $438,930,443 worth of Denali Therapeutics Inc stock and bought 275,000 units worth $4,950,000 . The most active insiders traders include Llc Fmr, Douglas Kakdl, L.P.Crestlin... y Jay T Flatley. On average, Denali Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,606,006. The most recent stock trade was executed by Vicki L Sato on 3 September 2024, trading 3,080 units of DNLI stock currently worth $77,000.
denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).
Denali Therapeutics Inc executives and other stock owners filed with the SEC include: